Comparing the current results to its competitors, Dynavax Technologies reported Revenue increase in the 3 quarter 2025 by 17.67 % year on year, while most of its competitors have experienced contraction in revenues by -1.85 %, achieved in the same quarter.
Dynavax Technologies Corporation Net Income in the 3 quarter 2025 grew year on year by 53.05%, faster than the Dynavax Technologies's competitors average income growth of 24.52 %
Dynavax Technologies's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industry, focusing on vaccines and adjuvants. Its products and development programs compete with several commercially available vaccines and adjuvants. Multiple companies and institutions, including Pfizer, BioNTech SE, Curevo Vaccine, Moderna, Inc., GSK, Merck, and VBI Vaccines Inc., are developing vaccines and adjuvants that may compete directly or indirectly with the company's marketed products and those under development. The company’s HEPLISAV-B hepatitis B vaccine competes with Engerix-B and Twinrix from GSK, Recombivax-HB from Merck, and PreHevbrio from VBI Vaccines Inc. The company utilizes the CpG 1018 adjuvant, which it considers effective and sustainable compared to other adjuvants derived from shark squalene or tree bark; however, competitive success in sales is not guaranteed.
Overall company sales advanced by 17.67 % Dynavax Technologies outperformed its competitors in this segment and improved market share, to approx. 0.18 %. << More on DVAX Market Share.
*Market share is calculated based on total revenue.
Publicly Traded Peers of Dynavax Technologies Corporation
Xbiotech Inc Share Performance
-19.70%
One Year
Xbiotech Inc
Profile
Xbiotech Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic antibodies. They seek to address unmet medical needs by leveraging their proprietary True Human antibody technology.
Novavax Inc is a biotechnology company focused on the discovery, development, and commercialization of novel vaccines. They aim to leverage their proprietary recombinant nanoparticle vaccine technology platform to address a wide range of infectious diseases. By collaborating with partners and conducting clinical trials, Novavax works towards bringing innovative vaccines to the global market.
The business model of Innovation1 Biotech Inc involves developing and commercializing innovative biotechnological products and solutions for various industries. The company focuses on research, development, and manufacturing, aiming to provide cutting-edge biotech solutions that meet the needs of diverse markets.
Matinas Biopharma Holdings Inc operates as a clinical-stage biopharmaceutical company. Their business model centers around developing therapeutics through the utilization of lipid nano-crystal (LNC) platform technologies. These technologies enable the effective delivery of drugs to improve patient outcomes in various diseases and conditions such as fungal infections, viral infections, and cancer.
Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.
Sources:
Dynavax Technologies Corporation’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Dynavax Technologies Corporation versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
